EUCTR2020-003083-98-GB进行中（未招募）1 期
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance
Ellipses Pharma Limited0 个研究点目标入组 384 人开始时间: 2020年10月1日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 384
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients must meet all the following inclusion criteria to be eligible for inclusion in the study:
- •1. Patients age =18 years of age at the time of informed consent
- •2. Ability to understand and provide written informed consent prior to undergoing any study procedures
- •3. Life expectancy of > 3 months, as estimated by the investigator
- •4. Histologically confirmed diagnosis (cytology alone excluded) with highgrade serous ovarian cancer or high-grade endometrioid ovarian cancer, including primary peritoneal or fallopian tube cancer
- •5. BRCA mutational status is known (germline and somatic). (For Patients in Phase 2A, status does not need to be known prior to enrolment)
- •6. HRD status is known. (For Patients in Phase 2A, status does not need to be known prior to enrolment)
- •7. At least 1 measurable lesion to assess response by RECIST v1.1 criteria
- •8. Archival tumour sample must be available. In the absence of an archival tumour biopsy, a tumour tissue biopsy will need to be collected prior to enrolment
- •9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at Screening
- •10. Normal organ and bone marrow function:
- •Haemoglobin = 9.0 g/dL
- •Absolute neutrophil count (ANC) = 1.5 x 109
- •Lymphocyte count = 0.5 x 109
- •Platelet count = 100 x 109
- •Total bilirubin = 1.5 institutional upper limit normal (ULN)
- •Serum albumin = 2.5 g/dL
- •AST and ALT = 2.5 x ULN, unless liver metastases are present in which case they must be = 5 x ULN
- •Serum creatinine = 1.5 x ULN or calculated creatinine clearance >50mL/min (calculated using the Cockroft-Gault formula) for patients with creatinine levels above institutional normal
- •Patients not receiving anti-coagulant medication must have an INR of = 1.5 and an aPTT = 1.5 x ULN
- •11. In the opinion of the investigator, all other relevant medical conditions must be well-managed and stable for at least 28 days prior to first administration of study drug
- •12. Willing and able to participate in all required evaluations and procedures in this study protocol
- •13. Contraception. Each female subject of childbearing potential must agree to use a highly effective method of contraception (i.e., a method with less than 1% failure rate per year [e.g., sterilisation, hormone implants, hormone injections, some intrauterine devices, vasectomized partner, or combined birth control pills]) from screening until 120 days after the last dose of EP0057. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative serum or urine pregnancy test within 24 hours prior to EP0057 dosing on Day 1 of each Cycle (and must not be lactating). Each female subject will be considered to be of childbearing potential unless she has been surgically sterilised by hysterectomy or bilateral tubal ligation/salpingectomy or has been postmenopausal for at least 1 year.
- •Cohort 1 patients (Phase 2A and 2B) must be/have:
- •14. PARP inhibitor naïve
- •15. Received no more than 1 prior line of therapy which must be platinum based chemotherapy
- •16. Either: Stable disease (SD) following treatment with first line platinum-based
- •chemotherapy OR Primary platinum resistant disease defined by progressive disease (PD) within = 1 and = 6 months after completion of first line platinum-based chemotherapy
- •Cohort 2 patients (Phase 2A and 2B) must have:
- •18. Received at least 2 prior lines of treatment, 1 of which must be platinum-based chemotherapy
- •19. Received a PARP inhibitor in the maintenance setting as their most recent treatment follo
排除标准
- •1. Non-epithelial tumour of the ovary, the fallopian tube or the peritoneum
- •2. Ovarian tumours of low malignant potential or low grade
- •3. Prior treatment with a topoisomerase I inhibitor
- •4. Potent inhibitors or inducers of CYP3A4
- •5. Concurrent treatment with Coumadin (warfarin)
- •6. History of stroke, transient ischemic attack (TIA), or myocardial infarction, within 6 months prior to C1D1
- •7. Brain and/or leptomeningeal metastases that are symptomatic or untreated or that require current therapy. Brain imaging must not be older than 12 weeks (at the start of screening). Results with
- •abnormal/unexpected findings of brain MRI should be discussed with the Medical Monitor as part of the screening process
- •8. Systemic anti-cancer therapy for the disease under study within 3 weeks, or 5 half-lives, whichever is longer, of the first dose of study drug
- •9. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 2 toxicities, which in the opinion of the Investigator should not exclude the patient. Ongoing Grade 1 toxicities should be discussed with and approved by the Medical Monitor prior to inclusion
- •10. Patients considered at higher baseline risk for new onset cystitis should be discussed by the Investigator and Medical Monitor prior to enrolment
- •11. Patients with a history, or features suggestive, of bone marrow dysplasia or myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML)
- •12. Confirmed QTcF > 470 msec on screening ECG or congenital long QT syndrome
- •13. Receiving an investigational anti-cancer treatment concurrently or within 3 weeks or 5 half-lives of either the parent drug or any active metabolite, whichever is longer, prior to the first dose of study drug
- •14. Any evidence of severe or uncontrolled systemic conditions (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol
- •15. Hypersensitivity to EP0057 or any of its excipients
- •16. Known history of human immunodeficiency virus infection (HIV) (testing is not required), active infection with SARS-CoV-2, hepatitis B virus (HBV) or hepatitis C virus (HCV) per institutional protocol. Testing for HBV or HCV status is not necessary unless clinically indicated or the patient has a history of HBV or HCV infection. All patients should be tested for an active SARS-CoV-2 infection with an approved diagnostic test kit
- •17. Malignant disease other than that being treated in this study, with the following exceptions:
- •Malignancies that were treated curatively and have not recurred within 2 years prior to study treatment
- •Completely resected basal cell and squamous cell skin cancers
- •Any malignancy considered to be indolent and that has never required therapy
- •Completely resected carcinoma in situ of any type
- •18. Any medical condition that would, in the investigator’s judgment, prevent the patient’s participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results
- •19. Any major surgical procedure (in the investigator’s judgement) within 2 weeks of the first dose of study drug
- •20. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation)
- •21. Palliative radiotherapy (e.g., for pain or bleeding) within 6
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patientsAdvanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naïveCohort 2 – had at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenanceMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003083-98-HUEllipses Pharma Limited384
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of Lerociclib in participants with advanced breast cancer.MedDRA version: 20.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10006289Term: Benign and malignant breast neoplasmsSystem Organ Class: 100000004872MedDRA version: 20.0Level: HLTClassification code 10006290Term: Breast and nipple neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Metastatic breast cancerEUCTR2021-005238-40-ITEQRx International, Inc.100
进行中（未招募）
1 期
A study assessing the efficacy and safety of an investigational drug called fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participantsEUCTR2020-002858-24-SEClementia Pharmaceuticals Inc, an Ipsen Company98
尚未招募
2 期
A Phase 2 study to assess the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of fibrodysplasia ossificans progressiva in male and female paediatric and adult participantsNL-OMON54489Ipsen Pharmaceuticals5
招募中
2 期
A study assessing the efficacy and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for FOPfibrodysplasia ossificans progressivaJPRN-jRCT2041220080egar Karimian4